Remdesivir Medicine Market Will Hit Big Revenues In Future | Sanofi, Gilead Sciences, GlaxoSmithKline – Press Release

Remdesivir Medicine Market Will Hit Big Revenues In Future | Sanofi, Gilead Sciences, GlaxoSmithKline

Remdesivir Medicine Comprehensive Study by Application (Ebola Virus Disease, Marburg Virus Infection, Possible COVID-19 Treatment), Administration (Oral, Intravenous), End-users (Hospitals, Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Online Channel, Offline Channel) Players and Region – Global Market Outlook to 2025.

Global Remdesivir Medicine Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Global Remdesivir Medicine industry with an attention on the Global market. The report gives key insights available status of the Global Remdesivir Medicine producers and is an important wellspring of direction and course for organizations and people keen on the business. By and large, the report gives an inside and out understanding of 2020-2025 worldwide Remdesivir Medicine Market covering extremely significant parameters.

Key Players in This Report Include,
Gilead Sciences, Inc. (United States), Hainan Haiyao Co., Ltd. (China), Sanofi S.A. (France), GlaxoSmithKline plc (United Kingdom) and Cipla (India)

Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/128698-global-remdesivir-medicine-market

Brief Summary of Global Remdesivir Medicine:
Remdesivir medicine is an anti-viral medication being studied as a possible post-infection treatment for COVID-19 illness. This medicine is a nucleotide analog, specifically an adenosine analog, which inserts into viral RNA chains causing their premature termination. It was developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections. It is an investigational antiviral compound undergoing clinical trials in China, the United States and the United Kingdom as a potential treatment for COVID-19. It is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use.

Market Drivers

  • Increased Prevalence of COVID-19 Illness
  • Highly Effective Anti-viral Medicine

 

Market Trend

  • High Demand for Coronavirus Disease Treatment

 

Restraints

  • Lack of Clinical Evidence for COVID-19 Treatment

 

Opportunities

  • Increasing Number of Patients affecting COVID-19
  • Growth in the Healthcare Industry

 

Challenges

  • Stringent Government Rules and Regulations

This research report represents a 360-degree overview of the competitive landscape of the Global Remdesivir Medicine Market. Furthermore, it offers massive data relating to recent trends, technological, advancements, tools, and methodologies. The research report analyzes the Global Remdesivir Medicine Market in a detailed and concise manner for better insights into the businesses.

Regions Covered in the Global Remdesivir Medicine Market:

  • The Middle East and Africa (South Africa, Saudi Arabia, UAE, Israel, Egypt, etc.)
  • North America (United States, Mexico & Canada)
  • South America (Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, etc.)
  • Europe (Turkey, Spain, Turkey, Netherlands Denmark, Belgium, Switzerland, Germany, Russia UK, Italy, France, etc.)
  • Asia-Pacific (Taiwan, Hong Kong, Singapore, Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia).


Enquire for customization in Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/128698-global-remdesivir-medicine-market

The research study has taken the help of graphical presentation techniques such as infographics, charts, tables, and pictures. It provides guidelines for both established players and new entrants in the Global Remdesivir Medicine Market.

The detailed elaboration of the Global Remdesivir Medicine Market has been provided by applying industry analysis techniques such

Read more

Sanofi, GSK to supply vaccine doses to WHO-backed alliance

PARIS (Reuters) – French drugmaker Sanofi and Britain’s GlaxoSmithKline will supply 200 million doses of their COVID-19 candidate vaccine to a global inoculation scheme backed by the World Health Organization.

There is no internationally-approved treatment against COVID-19, which has killed more than 1.16 million people, and the two companies’ vaccine is still undergoing phase 1 and 2 trials, from which first results are expected by late November or early December.

They said on Wednesday they had signed a statement of intent with vaccine alliance GAVI, which is coordinating the global scheme, known as COVAX.

COVAX, which aims to deliver 2 billion vaccine doses around the world by the end of 2021, has already sealed agreements this year with AstraZeneca and Novavax.

It aims to discourage national governments from hoarding COVID-19 vaccines and to focus vaccinating the most high-risk people first in every country.

More than 180 nations including China have joined the plan but some, including the United States, have opted to stick with their own supply deals.

Sanofi and GSK signed a $2.1 billion deal with Washington during the summer to supply it with more than 100 million doses of the same vaccine, which they hope to present for regulatory approval next year.

The companies also have similar agreements with the European Union, Britain and Canada.

Their candidate vaccine uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines. It will be coupled with an adjuvant, a substance that acts as a booster to the vaccine, made by GSK.

Sanofi is also working on another vaccine project with U.S. company Translate Bio that will use a technology known as messenger RNA (mRNA) which instructs cells in the body to make coronavirus proteins that then produce an immune response.

Clinical trials for this project are expected to start in the fourth quarter.

COVAX is co-led by GAVI, the WHO and the Coalition for Epidemic Preparedness Innovations (CEPI).

(Reporting by Vishwadha Chander in Bengaluru, Matthias Blamont in Paris; Editing by Shounak Dasgupta and John Stonestreet)

Source Article

Read more

Sanofi, GSK to provide 200 million Covid vaccine doses to WHO immunization program

A health worker wearing a protective mask works in a lab during clinical trials for a Covid-19 vaccine at Research Centers of America in Hollywood, Florida, U.S.

Eva Marie Uzcategui | Bloomberg | Getty Images

European drugmakers Sanofi and GlaxoSmithKline will provide 200 million doses of their Covid-19 vaccine to the World Health Organization’s global immunization partnership COVAX, which seeks to ensure coronavirus vaccines are distributed equitably across the world, the companies announced Wednesday.

Global health organizations including the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations and the WHO are leading the COVAX effort, which is focused on first vaccinating the most high-risk people in every country. The deal is contingent on the vaccine winning regulatory approval, the companies said in a statement.

The initiative aims to deliver 2 billion doses of the vaccine by the end of 2021, though it’s now competing for scarce doses of promising vaccines with some wealthy countries like the United States that didn’t join the COVAX facility and procured hundreds of millions of doses on their own.

“Since we started working on the development of COVID-19 vaccines, GSK has pledged to make them available to people around the world,” Roger Connor, president of GSK Vaccines, said in a statement. He added that “this has the potential to be a significant contribution to the global fight against COVID-19.”

More than 180 countries have so far joined COVAX, the companies said. WHO says at least 78 higher-income countries, including China and the United Kingdom have signed on.

The WHO has previously acknowledged that there won’t be enough vaccine doses for everyone in the world once one candidate is authorized for use. The UN health agency has published allocation principles that countries can use to craft a plan for who would first receive the immunization when the country receives doses.

The WHO says it intends for all countries to receive enough doses to vaccinate 20% of their population, excluding countries that request fewer doses than that, before any country receives more doses.

Thomas Triomphe, executive vice president and global head of Sanofi Pasteur, said their provision of doses demonstrates the company’s “commitment to global health and ensures our COVID-19 vaccines are affordable and accessible to those most at risk, everywhere in the world.”

Sanofi and GSK’s vaccine is further behind in clinical development than some of the front-runners like Pfizer, Moderna and AstraZeneca, which are all in late-stage trials. Sanofi and GSK said they anticipate results from their phase two trial in early December and will then launch a large phase three trial. The companies plan to request regulatory approval for the vaccine, if the data supports it, in the first half of 2021.

WHO Director-General Tedros Adhanom Ghebreyesus has previously said he’s less concerned with acquiring doses of the first available vaccine and more concerned with acquiring a large amount of doses of all vaccines.

“The first vaccine to be approved may not be the best,” he said last month. “The more shots on

Read more